CompletedPhase 1NCT00002765

Immunotoxin in Treating Patients With Leukemia or Lymphoma

Studying Acute mast cell leukemia

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Robert Kreitman, MD
National Cancer Institute (NCI)
Intervention: LMB-2 immunotoxin(biological)
Eligibility: 18 years · All sexes
Timeline: 1996

Study locations (2)

Laboratory of Molecular Biology, Bethesda, Maryland, United States
Medicine Branch, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00002765 on ClinicalTrials.gov

Other trials for Acute mast cell leukemia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1, PHASE2NCT06213636
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Essen Biotech

See all trials for Acute mast cell leukemia →

← Back to all trials